As you may recall, on February 28, 2023, the Drug Enforcement Agency (DEA) proposed new rules, Telemedicine Prescribing of Controlled Substances When the Practitioner and the Patient Have Not Had a Prior In-Person Medical Evaluation, which eliminate the pandemic-era flexibilities for prescribing controlled substances via telemedicine.
In response to public listening sessions that DEA hosted on September 12 and 13, 2023, DEA and HHS are further extending the pandemic-era telemedicine flexibilities through December 31, 2024.
We have updated AAPPN’s roadmap to DEA’s current proposed new rules. With this online tool, you can find a roadmap for prescribing controlled substances under the proposed DEA rules, including:
- Schedule III, IV, or V non-narcotic controlled medications
- Buprenorphine as medication for opioid use disorder
- Schedule II and/or narcotic controlled medications
In addition to the DEA prescriber guidelines, you will also find guidance on what you will need to maintain appropriate written or electronic patient logs.
If you have any questions, please email Chris Crosser at gro.nppaa@sirhc.